Emphysema is a serious lung disease afflicting more than 30 million people worldwide. Pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease.

Right Therapy for the Right Patient

The Pulmonx solution, comprised of the Chartis Pulmonary Assessment System and the Zephyr® Endobronchial Valve, offers a minimally invasive treatment for patients with severe emphysema. The technology identifies appropriate candidates for the therapy and provides a treatment option to significantly improve the lives of patients.

Effective Outcomes

Icon of a Chart

A decade of clinical success with over 10,000 patients treated.

Icon of Documents

Over 110 publications documenting the safety, efficacy and long-term survival benefits for patients treated with the Zephyr valve.

Icon of a Globe

The Zephyr valve features the broadest clinical experience of any minimally invasive emphysema treatment.

SUSTAINED & MEANINGFUL Patient Benefits

With severe emphysema, Keith found it difficult to walk up more than one step. After receiving Zephyr valves, Keith breathes easier and can walk up an entire flight of stairs.